Skip to main content
. 2000 Oct 16;192(8):1197–1204. doi: 10.1084/jem.192.8.1197

Figure 2.

Figure 2

Human ECs and PMNs: novel trihydroxy-containing compounds LC/MS/MS. (A) HUVECs treated with IL-1β (24 h) and ASA. (B) Human PMNs (∼ 30 × 106/ml) incubated (30 min, 37°C) with serum-treated zymosan (100 ng/ml) and acetylated ASA-recombinant COX-2–derived products from EPA. (C) MS/MS of 5,12,18R-triHEPE (see text for ions and fragmentation). (D) MS/MS of 15-epi-LXA5. Results are representative of n = 3–5 for PMNs and n = 3 for ECs.